Metformin and prostate cancer mortality: a meta-analysis

Cancer Causes and Control

Volumn 27, Issue 1, 2016, Pages 105-113

  Stopsack, Konrad H ^a   Ziehr, David R ^b,c   Rider, Jennifer R ^a,d   Giovannucci, Edward L ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biochemical recurrence; Diabetes mellitus; Meta analysis; Metformin; Mortality; Prostate cancer

Indexed keywords

METFORMIN;

DIABETES MELLITUS; HUMAN; MALE; META ANALYSIS; MORTALITY; PROSTATE TUMOR; RETROSPECTIVE STUDY; RISK;

DIABETES MELLITUS; HUMANS; MALE; METFORMIN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK;

EID: 84953356462     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0687-0     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
2. Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H (2012) Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control 23:769–777
3. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 15:2056–2062
4. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25:329–338
5. Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963–1972
6. Flavin R, Zadra G, Loda M (2011) Metabolic alterations and targeted therapies in prostate cancer. J Pathol 223:283–294
7. Ben Sahra I, Laurent K, Loubat A et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576–3586
8. DeCensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451–1461
9. Zhang P, Li H, Tan X, Chen L, Wang S (2013) Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 37:207–218
10. Yu H, Yin L, Jiang X et al (2014) Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS ONE 9:e116327
11. Raval AD, Thakker D, Vyas A, Salkini M, Madhavan S, Sambamoorthi U (2015) Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 18:110–121
12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
13. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (2005) Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 20(3):CD002966
14. Stephenson AJ, Kattan MW, Eastham JA et al (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24:3973–3978
15. Margel D, Urbach DR, Lipscombe LL et al (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069–3075
16. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
18. Jüni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46
19. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
20. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomark Prev 23:2111–2118
21. Xu H, Aldrich MC, Chen Q et al (2015) Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc 22(1):179–191
22. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ (2013) Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63:709–716
23. Häggström C, Stocks T, Nagel G et al (2014) Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology 25:823–828
24. Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087
25. He XX, Tu SM, Lee MH, Yeung SC (2011) Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22:2640–2645
26. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76:1240–1244
27. D’Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH (2003) Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 169:1320–1324
28. Margel D, Urbach D, Lipscombe LL et al (2013) Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 105:1123–1131
29. Penney KL, Stampfer MJ (2013) The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol 31:3054–3055
30. Popiolek M, Rider JR, Andren O et al (2013) Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 63:428–435
31. Patorno E, Garry EM, Patrick AR et al (2015) Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. Drug Saf 38:295–310
32. Walker AM (1996) Confounding by indication. Epidemiology 7:335–336
33. Lee H, Kuk H, Byun SS, Lee SE, Hong SK (2015) Preoperative glycemic control status as a significant predictor of biochemical recurrence in prostate cancer patients after radical prostatectomy. PLoS ONE 10:e0124761
34. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665–2673
35. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920
36. IntHout J, Ioannidis JP, Borm GF (2014) The Hartung–Knapp–Sidik–Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian–Laird method. BMC Med Res Methodol 14:25
37. Rothermundt C, Hayoz S, Templeton AJ et al (2014) Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol 66:468–474
38. Joshua AM, Zannella VE, Downes MR et al (2014) A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17:252–258
39. Allott EH, Abern MR, Gerber L et al (2013) Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 16:391–397
40. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ (2014) Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 32(43):e1–e7
41. Spratt DE, Zhang Z, Zelefsky MJ (2013) Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay’s letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709–16. Eur Urol 64:e29–e30